

Ewing's Sarcoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/E29CDF780F1EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E29CDF780F1EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Ewing's Sarcoma – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ewing's Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ewing's Sarcoma Understanding

Ewing's Sarcoma: Overview

Ewing's sarcoma is a cancerous (malignant) tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. There is no known cause of Ewing's sarcoma. Symptoms of Ewing's sarcoma includes: pain, swelling, or stiffness in the area of the tumor (arms, legs, chest, back, or pelvis) for weeks or months. Physical exam, X-ray, Bone scan, CT scan, MRI are most used diagnostic procedures for Ewing sarcoma. The main treatments for ewing sarcoma are chemotherapy, surgery, and radiation. These treatments are often used in some combination with each other.

'Ewing's Sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ewing's Sarcoma pipeline landscape is provided which includes the disease overview and Ewing's Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Ewing's Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ewing's Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ewing's Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Ewing's Sarcoma.

Ewing's Sarcoma Emerging Drugs Chapters

This segment of the Ewing's Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ewing's Sarcoma Emerging Drugs

Vigil immunotherapy: Gradalis, Inc.

Phase III clinical trials are being conducted by gradalis, Inc. for Intradermal autologous Vigil immunotherapy in combination with irinotecan and temozolomide in subjects with metastatic Ewing's sarcoma Family of Tumors (ESFT).

Eribulin mesylate: Eisai, Inc.

Eribulin Mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance with antineoplastic activity. Eribulin mesylate clinical trials are going on in

phase II stage of development by eisai, Inc for Ewing sarcoma.

Further product details are provided in the report.....

Ewing's Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Ewing's Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ewing's Sarcoma

There are approx. 10+ key companies which are developing the therapies for Ewing's Sarcoma. The companies which have their Ewing's Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Gradalis, Inc.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ewing's Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ewing's Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ewing's Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ewing's Sarcoma drugs.

Ewing's Sarcoma Report Insights

Ewing's Sarcoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ewing's Sarcoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Ewing's Sarcoma drugs?

How many Ewing's Sarcoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ewing's Sarcoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ewing's Sarcoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ewing's Sarcoma and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- Ewing's Sarcoma: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Ewing's Sarcoma – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Ewing's Sarcoma companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- Ewing's Sarcoma Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
 - Comparative Analysis
- Vigil immunotherapy: Gradalis, Inc.
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Eribulin mesylate: Eisai, Inc.
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

SP-2577: Salarius Pharmaceuticals, LLC

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

NV103: Nanovalent pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Ewing's Sarcoma Key Companies

Ewing's Sarcoma Key Products

Ewing's Sarcoma- Unmet Needs

Ewing's Sarcoma- Market Drivers and Barriers

Ewing's Sarcoma- Future Perspectives and Conclusion

Ewing's Sarcoma Analyst Views

Ewing's Sarcoma Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Ewing's Sarcoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Ewing's Sarcoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Ewing's Sarcoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/E29CDF780F1EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E29CDF780F1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970